# Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Source: https://onco.cc/trials/nct05451043/  
OnCo record `nct05451043` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab, tremelimumab, gemcitabine and other drugs in gallbladder cancer and other biliary tract cancers, run by AHS Cancer Control Alberta, now recruiting.

## Summary

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) is a phase 2 interventional study registered as NCT05451043 by AHS Cancer Control Alberta, with a registry enrolment figure of 62 participants, started 2023-07-05 and due to reach its primary completion in 2026-10-01. Interventions recorded: Durvalumab, Gemcitabine, Nab paclitaxel, Tremelimumab, Propranolol, Cisplatin. Conditions listed: Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma. Sites: Canada. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT05451043
- Phase: 2
- Setting: A Study to Evaluate the Efficacy of Propranolol in Boosting Immunotherapy in Hepatocellular Carcinoma, Cholangiocarcinoma and Pancreatic Adenocarcinoma
- Sponsor: AHS Cancer Control Alberta
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT05451043: https://clinicaltrials.gov/study/NCT05451043

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct05451043.json